HGF and neoplasm: A previous analysis of biomarkers in samples from phase 3 clinical trials of sorafenib treatment showed that patients with lower plasma HGF concentrations before treatment might have a higher survival rate, emphasizing that tumor-related M2 macrophages and HGF in tumors are of great importance in response to sorafenib therapy (74).